Loading…
QUINORIC is a brand name for Hydroxychloroquine. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Adults Treatment of rheumatoid arthritis, discoid and systemic lupus erythematosus, and dermatological conditions caused or aggravated by sunlight. Paediatric Population Treatment of juvenile idiopathic arthritis (in combination with other therapies) , discoid and systemic lupus erythematosus.
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Adults (including the elderly) The minimum effective dose should be employed. 5 mg/kg/day (calculated from ideal body weight and not actual body weight) and will be either 200 mg or 400 mg per day.
In patients able to receive 400mg daily:
Initially 400 mg daily in divided doses. The dose can be reduced to 200 mg when no further improvement is evident. The maintenance dose should be increased to 400 mg daily if the response lessens. 5 mg/kg/day based on ideal body weight.
The 200 mg tablet is therefore not suitable for use in children with an ideal body weight of less than 31kg. . Method of administration The tablets are for oral administration. Each dose should be taken with a meal or glass of milk. Hydroxychloroquine is cumulative in action and will require several weeks to exert its beneficial effects, whereas minor side effects may occur relatively early.
For rheumatic disease treatment should be discontinued if there is no improvement by 6 months. In light-sensitive diseases, treatment should only be given during periods of maximum exposure to light.
The following CIOMS frequency rating is used, when applicable:
Very common (≥1/10); Common (≥1/100 to <1/10); Uncommon (≥1/1,000 to <1/100) ; Rare (≥1/10,000 to <1/1,000); Very rare (<1/10,000); Not known (frequency cannot be estimated from the available data). 4) Hydroxychloroquine may precipitate or exacerbate porphyria Common Affect liability Uncommon Nervousness Psychiatric disorders Not known Suicidal behaviour, psychosis, depression, hallucinations, anxiety, agitation, confusion, delusions, mania and sleep disorders Common headache Uncommon dizziness Nervous system disorders Not known Convulsions have been reported with this class of drugs.
4) Common Blurring of vision due to a disturbance of accommodation which is dose dependent and reversible Uncommon Retinopathy with changes in pigmentation and visual field defects can occur, but appears to be uncommon if the recommended daily dose is not exceeded.
In its early form it appears reversible on discontinuation of hydroxychloroquine sulfate. If allowed to develop, there may be a risk of progression even after treatment withdrawal. Patients with retinal changes may be asymptomatic initially, or may have scotomatous vision with paracentral, pericentral ring types, temporal scotomas and abnormal colour vision.
Corneal changes including oedema and opacities have been reported. They are either symptomless or may cause disturbances such as haloes, blurring of vision or photophobia. They may be transient and are reversible on stopping treatment.
Eye disorders Not known Cases of maculopathies and macular degeneration have been reported (the onset ranging from 3 months to several years of exposure to hydroxychloroquine) and may be irreversible Uncommon Vertigo, tinnitusEar and labyrinth disorders Not known Hearing loss Common Skin rash, Pruritus Uncommon Pigmentation disorders in skin and mucous membranes, bleaching of hair, alopecia These usually resolve readily on stopping treatment.
Retinopathy The occurrence of retinopathy is very uncommon if the recommended daily dose is not exceeded. The administration of doses in excess of the recommended maximum is likely to increase the risk of retinopathy, and accelerate its onset.
All patients should have an ophthalmological examination before initiating treatment with Hydroxychloroquine. Thereafter, ophthalmological examinations must be repeated at least every 12 months. The examination should include testing visual acuity, careful ophthalmoscopy, fundoscopy and central visual field testing with a red target, and colour vision.
5mg/kg lean body weight. Absolute body weight used as a guide to dosage could result in an overdosage in the obese. • renal insufficiency • visual acuity below 6/8 • age above 65 years • cumulative dose more than 200 g. • concomitant use of hydroxychloroquine sulfate with drugs known to induce retinal toxicity, such as tamoxifen.
Hydroxychloroquine should be discontinued immediately in any patient who develops a pigmentary abnormality, visual field defect, or any other abnormality not explainable by difficulty in accommodation or presence of corneal opacities.
Patients should continue to be observed for possible progression of the changes. Patients should be advised to stop taking the drug immediately and seek the advice of their prescribing doctor if any disturbances of vision are noted, including abnormal colour vision.
8). Hypoglycaemia Hydroxychloroquine has been shown to cause severe hypoglycaemia including loss of consciousness that could be life threatening in patients treated with and without antidiabetic medications. Patients treated with hydroxychloroquine should be warned about the risk of hypoglycaemia and the associated clinical signs and symptoms.
Patients presenting with clinical symptoms suggestive of hypoglycaemia during treatment with hydroxychloroquine should have their blood glucose level checked and treatment reviewed as necessary. QT interval prolongation Hydroxychloroquine has the potential to prolong the QTc interval in patients with specific risks factors.
6).
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Hydroxychloroquine in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Skin and subcutaneous tissue disorders Not known • Bullous eruptions including erythema multiforme • Stevens-Johnson syndrome and toxic epidermal necrolysis • Drug Rash with Eosinophilia and Systemic Symptoms (DRESS syndrome) • Photosensitivity • Sweet’s syndrome and Severe cutaneous adverse reactions (SCARs) • exfoliative dermatitis, acute generalised exanthematous pustulosis (AGEP).
AGEP has to be distinguished from psoriasis, although hydroxychloroquine may precipitate attacks of psoriasis. It may be associated with fever and hyperleukocytosis. Outcome is usually favourable after drug withdrawal. Very common Abdominal pain, nauseaGastrointestinal disorders Common diarrhoea, vomiting These symptoms usually resolve immediately on reducing the dose or on stopping treatment.
9). 9) Chronic toxicity should be considered when conduction disorders (bundle branch block/atrioventricular heart block) as well as biventricular hypertrophy are found. Drug withdrawal may lead to recovery. Uncommon Sensory motor disordersMusculoskeletal and connective tissue disorders Not known Skeletal muscle myopathy or neuromyopathy leading to progressive weakness and atrophy of proximal muscle groups.
Myopathy may be reversible after drug discontinuation, but recovery may take many months. Depression of tendon reflexes and abnormal nerve conduction studies. Phospholipidosis mimicking Fabry disease Uncommon Abnormal liver function testsHepatobiliary disorders Not known Drug-induced liver injury (DILI) including hepatocellular injury, cholestatic liver injury, acute hepatitis, mixed hepatocellular/cholestatic liver injury and fulminant hepatic failure Reporting of side effects Reporting of suspected adverse reactions after the marketing authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
5) as this may lead to an increased risk for ventricular arrhythmias. The magnitude of QT prolongation may increase with increasing concentrations of the drug. Therefore, the recommended dose should not be exceeded. 9). Clinical monitoring for signs and symptoms of cardiomyopathy is advised and with hydroxychloroquine sulfate should be discontinued if cardiomyopathy develops.
8). Bone marrow depression Although the risk of bone marrow depression is low, periodic blood counts are advisable as anaemia, aplastic anaemia, agranulocytosis, a decrease in white blood cells, and thrombocytopenia have been reported.
Hydroxychloroquine should be discontinued if abnormalities develop. 8). All patients on long-term therapy should undergo periodic examination of skeletal muscle function and tendon reflexes. 8) Potential carcinogenic risk Experimental data showed a potential risk of inducing gene mutations.
3). In humans, there is insufficient data to rule out an increased risk of cancer in patients receiving long- term treatment. Caution should also be applied when it is used in the following: • patients with hepatic or renal disease, and in those taking drugs known to affect those organs.
Estimation of plasma hydroxychloroquine levels should be undertaken in patients with severely compromised renal or hepatic function and dosage adjusted accordingly. • patients with severe gastrointestinal, neurological or blood disorders.
• patients with a sensitivity to quinine, those with glucose-6-phosphate dehydrogenase deficiency, those with porphyria cutanea tarda which can be exacerbated by hydroxychloroquine and in patients with psoriasis since it appears to increase the risk of skin reactions.
Paediatric populations Small children are particularly sensitive to the toxic effects of 4-aminoquinolines; therefore patients should be warned to keep Hydroxychloroquine out of the reach of children. Dermatological reactions Life-threatening cutaneous reactions Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with the use of Hydroxychloroquine.
Patients should be advised of the signs and symptoms and monitored closely for skin reactions. The highest risk for occurrence of SJS or TEN is within the first weeks of treatment. g. progressive skin rash often with blisters or mucosal lesions) are present, […]